A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Tirabrutinib in Subjects With Antihistamine-Resistant Chronic Spontaneous Urticaria
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Tirabrutinib (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Sponsors Gilead Sciences
Most Recent Events
- 22 Jul 2021 Planned initiation date changed from 28 May 2021 to 1 Jul 2021.
- 22 Jul 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.(Development program terminated )
- 13 May 2021 Planned initiation date changed from 1 Apr 2021 to 28 May 2021.